Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.

Abbott India posts Q2 profit rise on strong demand, price hikes

NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers. This data breach has led to concerns over the security of sensitive private information entrusted to ALECU.

Levi & Korsinsky, LLP Investigates Abbott Laboratories Employees Credit Union ("ALECU") Data Breach

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers. This data breach has led to concerns over the security of sensitive private information entrusted to ALECU.

Abbott Laboratories Employees Credit Union ("ALECU") Data Breach - Levi & Korsinsky, LLP Launches Investigation

Reckitt Benckiser Group PLC

Shares of Abbott Laboratories (ABT) are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after a jury cleared the two infant formula makers of liability for a boy's debilitating intestinal disease.

Abbott, Reckitt Stocks Gain as Baby Formula Makers Score Rare Legal Win

Abbott stock surged early Friday after a jury decided baby formula from Abbott and Mead Johnson are not responsible for a boy's disease. The post Abbott Surges After Avoiding Another 'Eye-Popping' Verdict In Baby Formula Trial appeared first on Investor's Business Daily.

Abbott Surges After Avoiding Another 'Eye-Popping' Verdict In Baby Formula Trial

Abbott Laboratories shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas' risks.

Abbott shares rise after securing first win in premature infant formula trial

A court in St. Louis, Missouri ruled in favor of Abbott Laboratories and Reckitt Benckiser over claims their specialized baby formula caused users to develop a bowel disease called NEC

Abbott Labs and Reckitt Benckiser shares surge on court's baby formula ruling

Abbott and Reckitt unit Mead Johnson are not responsible for a young boy's debilitating intestinal disease, a jury found on Thursday in a lawsuit accusing them of failing to warn of their premature baby formulas' risks, a victory for the two companies following large losses in similar trials.

Abbott, Reckitt cleared of liability in latest preterm formula case

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers.This data breach has led to concerns over the security of sensitive private information entrusted ALECU. WHAT'S THIS ABOUT?

Levi & Korsinsky, LLP Announces Investigation Abbott Laboratories Employees Credit Union (“ALECU”)

A lawyer for a Missouri mother on Wednesday asked a jury to make Abbott and Reckitt's Mead Johnson pay a total of more than $6 billion in the latest trial over claims that the companies' formulas for premature babies caused a severe intestinal illness.

Jury asked to award more than $6 billion in preterm formula case against Abbott, Reckitt's Mead

Intuitive Surgical

UnitedHealth Group

Investors looking for health-related buy-and-hold stocks must look no further than this list. The stocks on this list are market leaders in healthcare, producing sustainable growth with healthy balance sheets, impressive value, and broad market support.

These Are The Top Health Stocks to Own for Buy-and-Hold Investing

Investors feel optimistic about Abbott's robust strength in the Diagnostics and Nutrition business. Yet, unfavorable forex impacts are concerning.

Here's Why You Should Retain ABT Stock in Your Portfolio Now

Archer-Daniels-Midland Company

Albemarle

Becton, Dickinson and Co.

Franklin Resources

C.H. Robinson Worldwide

Genuine Parts

Hormel Foods

Medtronic

McCormick

Nordson

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

PepsiCo

PPG Industries

J. M. Smucker

SPDR S&P 500 ETF Trust

Stanley Black & Decker

Target

T. Rowe Price Group

The ProShares S&P 500 Dividend Aristocrats ETF went on a great run during Q3, gaining 11.6% during the quarter. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 39 months of tracking these strategies, all 3 strategies are generating a CAGR superior to NOBL while also offering a higher dividend yield.

My Best Dividend Aristocrats For November 2024

Abbott initiates the TEAM-HF trial to improve outcomes for advanced heart failure.

ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool and Abbott collaborate to integrate data, expand patient choice, and improve clinical workflows.

Tidepool Will Integrate With Abbott's FreeStyle Libre Portfolio for Seamless Cloud-to-Cloud Data

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers. This data breach has led to concerns over the security of sensitive private information entrusted to ALECU.

Abbott Laboratories Employees Credit Union (“ALECU”) Data Breach under Investigation by Levi & Korsinsky

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool and Abbott partner to integrate data, expand patient choice, and improve clinical workflows.

CORRECTING and REPLACING Tidepool Will Integrate With Abbott's FreeStyle Libre Portfolio for Seamless Cloud-to-Cloud Data

Seamless Data: Tidepool and Abbott's New Cloud-to-Cloud Integration Partnership

AbbVie

Johnson & Johnson

These healthcare stocks have fantastic dividend track records.

3 Dividend Growth Stocks You Can Buy and Hold Forever

CHICAGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Attorneys at the law firm FeganScott have launched an investigation into the Abbott Laboratories Employees Credit Union (ALEC) data breach, which, according to company reports, occurred during an August cyberattack against the Illinois-based credit union.

FeganScott Launches Investigation into Abbott Laboratories Employees Credit Union Data Breach

The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner in their disease progression ABBOTT PARK, Ill., Oct. 24, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new, first-of-its-kind clinical trial designed to improve outcomes in patients with worsening heart failure who could benefit from advanced therapy options.

Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure

OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.

Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt

Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive growth following a drop in Covid-test demand. The company reported 9% revenue growth in terms of pure organic sales, with several of its segments reeling in double-digit growth. ABT appears fairly valued, showing no strong buy or sell signals based on its P/E to EPS growth relationship.

News for Abbott Labs Stock (ABT)